Oncology Tests

TSP50™ is a Targeted Sequencing Panel covering 50 genes involved in cancer. This panel is ideal for patients diagnosed with ovarian cancer, breast cancer, prostate cancer and bladder cancer, providing analysis of genes that may offer suitable drug targets.

Postal and Delivery times are constantly changing. Whilst every effort is made to reduce time where possible this cannot always be achieved due to actions outside our control. The times quoted are from the time the final sample is received.

TSP22™ is a Targeted Sequencing Panel covering 22 genes associated with lung cancer, bowel cancer, melanoma and pancreatic cancer. For lung cancer, we are also able to screen for RNA fusions including ALK, RET, ROS-1 and NTRK-1.

Postal and Delivery times are constantly changing. Whilst every effort is made to reduce time where possible this cannot always be achieved due to actions outside our control. The times quoted are from the time the final sample is received.

Testing of the protein coding region of the genome (exome) covering more than 19,000 genes can be performed from FFPE cancer samples. For inherited diseases a blood sample would be required.

Postal and Delivery times are constantly changing. Whilst every effort is made to reduce time where possible this cannot always be achieved due to actions outside our control. The times quoted are from the time the final sample is received.

The assay covers 26 genes associated with soft tissue sarcomas: ALK, CAMTA1, CCNB3, CIC, EPC, EWSR1, FKHR, FUS, GLI1, HMGA2, JAZF1, MEAF6, MKL2, NCOA2, NTRK3, PDGFB, PLAG1, ROS1, SS18, STAT6, TAF15, TCF12, TFE3, TFG, USP6 and YWHAE.

Postal and Delivery times are constantly changing. Whilst every effort is made to reduce time where possible this cannot always be achieved due to actions outside our control. The times quoted are from the time the final sample is received.

TSP19™ is a Targeted Sequencing Panel covering 19 genes involved in myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML).

Postal and Delivery times are constantly changing. Whilst every effort is made to reduce time where possible this cannot always be achieved due to actions outside our control. The times quoted are from the time the final sample is received.

Our tumour mutational load assay has been designed in response to the need to determine if treatment utilising immune checkpoint inhibitors are likely to be of benefit in your particular clinical circumstances.

Postal and Delivery times are constantly changing. Whilst every effort is made to reduce time where possible this cannot always be achieved due to actions outside our control. The times quoted are from the time the final sample is received.

Our Inherited Cancer Panel specifically looks for inherited gene mutations in over 130 different genes associated with a wide range of hereditary cancers (including BRCA1, BRCA2 & PALB2). This screening test can be used to identify gene mutations responsible for hereditary cancers and to clarify the genetic risk for individuals with a family history of these hereditary cancers. It is a powerful tool that can help you reduce your risks or undertake measures that will help you detect hereditary cancers as early as possible.

Postal and Delivery times are constantly changing. Whilst every effort is made to reduce time where possible this cannot always be achieved due to actions outside our control. The times quoted are from the time the final sample is received.

As an ongoing commitment to patient care, EasyDNA has added additional comprehensive multigene panels for cancer analysis to its diagnostic next generation sequencing molecular testing range of assays. EasyDNA has associated NATA accredited laboratories in Australia to provide this comprehensive cancer analysis assay covering both DNA mutations and RNA fusion genes.

Postal and Delivery times are constantly changing. Whilst every effort is made to reduce time where possible this cannot always be achieved due to actions outside our control. The times quoted are from the time the final sample is received.

The quest to identify a relatively non-invasive, patient-friendly, effective cancer biomarker has continued and a solution to previous problems has now been found with the development of new technologies and techniques including sequencing technologies, massive parallel sequencing and highly sensitive quantitative polymerase chain reaction (PCR) testing.

Postal and Delivery times are constantly changing. Whilst every effort is made to reduce time where possible this cannot always be achieved due to actions outside our control. The times quoted are from the time the final sample is received.

This specialized panel includes analysis of the BRCA1 and BRCA2 genes. BRCA1 and BRCA2 gene mutations can increase your risk of breast and ovarian cancer and are implicated in a high number of breast cancer cases.

Postal and Delivery times are constantly changing. Whilst every effort is made to reduce time where possible this cannot always be achieved due to actions outside our control. The times quoted are from the time the final sample is received.